Patents by Inventor Kenneth Jeff Thrasher

Kenneth Jeff Thrasher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers
    Patent number: 9776992
    Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 3, 2017
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Robert Dean Dally, Timothy Barrett Durham, Kevin Robert Fales, Kwame Frimpong, Jefferson Ray McCowan, Frank George Njoroge, Timothy Alan Shepherd, Chong Si, Kenneth Jeff Thrasher, James Lee Toth, Zhipei Wu
  • 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS
    Publication number: 20170233378
    Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.
    Type: Application
    Filed: November 24, 2015
    Publication date: August 17, 2017
    Applicant: Eli Lilly and Company
    Inventors: Harold Burns BROOKS, Robert Dean DALLY, Timothy Barrett DURHAM, Kevin Robert FALES, Kwame FRIMPONG, Jefferson Ray MCCOWAN, Frank George NJOROGE, Timothy Alan SHEPHERD, Chong SI, Kenneth Jeff THRASHER, James Lee TOTH, Zhipei WU
  • COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE
    Publication number: 20140031287
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: August 20, 2013
    Publication date: January 30, 2014
    Applicant: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide
    Patent number: 8552039
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: October 8, 2013
    Assignee: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeil McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide
    Patent number: 8546581
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: October 1, 2013
    Assignee: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John Mcneill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Muralikrishna Valluri
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20110190205
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 4, 2011
    Applicant: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus JUNGHEIM, John McNeill MCGILL, III, Kenneth Jeff THRASHER, Robert Jason HERR, Muralikrishna VALLURI
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
    Patent number: 7947841
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: May 24, 2011
    Assignee: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Valluri Muralikrishna
  • COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE
    Publication number: 20100120876
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: December 11, 2009
    Publication date: May 13, 2010
    Applicant: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Robert Jason HERR, Louis Nickolaus JUNGHEIM, John McNeill MCGILL, III, Kenneth Jeff THRASHER, Muralikrishna VALLURI
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
    Patent number: 7662771
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: February 16, 2010
    Assignee: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20090239798
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Application
    Filed: November 3, 2008
    Publication date: September 24, 2009
    Applicant: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Muralikrishna Valluri
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20080214448
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: August 18, 2004
    Publication date: September 4, 2008
    Applicant: EMISPHERE TECHNOLOGIES INC.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Substituted dipeptides as growth hormone secretagogues
    Patent number: 7125840
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: October 24, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Britta Evers, Louis Nickolaus Jungheim, Brian Stephen Muehl, Gerd Ruehter, Kenneth Jeff Thrasher
  • Compounds and pharmaceutical compositions for inhibiting MRP1
    Patent number: 7101891
    Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: September 5, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Daniel Cohen, Louis Nickolaus Jungheim, Brian Stephen Muehl, Kenneth Jeff Thrasher
  • Compounds and methods for inhibiting MRP1
    Patent number: 7037921
    Abstract: The present invention relates to a compound of Formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Louis Nickolaus Jungheim, Kenneth Jeff Thrasher
  • Growth hormone secretagogues
    Patent number: 6992097
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Growth Hormone secretagogues
    Publication number: 20040122234
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: June 3, 2003
    Publication date: June 24, 2004
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Compounds and pharmaceutical compositions for inhibiting mrp1
    Publication number: 20040116460
    Abstract: The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Application
    Filed: September 25, 2003
    Publication date: June 17, 2004
    Inventors: Jeffrey Daniel Cohen, Louis Nickolaus Jungheim, Brian Stephen Muehl, Kenneth Jeff Thrasher
  • Methods and compounds for inhibiting MRP1
    Patent number: 6743794
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
  • Compounds and methods for inhibiting mrp1
    Publication number: 20040097507
    Abstract: The present invention relates to a compound of Formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Application
    Filed: September 25, 2003
    Publication date: May 20, 2004
    Inventors: Rosanne Bonjouklian, Louis Nikolaus Jungheim, Kenneth Jeff Thrasher
  • Substituted dipeptides as growth hormone secretagogues
    Publication number: 20040058971
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for usein the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: March 14, 2003
    Publication date: March 25, 2004
    Inventors: Jeffrey Alan Dodge, Britta Evers, Louis Nickolaus Jungheim, Brian Stephen Muehl, Gerd Ruehter, Kenneth Jeff Thrasher